# Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus

> **NCT04120623** · PHASE4 · UNKNOWN · sponsor: **Nanjing First Hospital, Nanjing Medical University** · enrollment: 100 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Dapagliflozin 10 MG
- **DRUG:** Insulin Aspart

## Key facts

- **NCT ID:** NCT04120623
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-01
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-02-28
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2019-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04120623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04120623, "Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04120623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*